Indefinite Delivery Contract SPE2DU25D1219

Award Date 8/1/25
Last Date to Order 12/31/36
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Indefinite Delivery Contract (IDC) SPE2DU25D3408 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. This single-award IDC, valued at $4,999,999, is for the provision of a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract aims to establish a Pharmaceutical Prime Vendor Global...
The Indefinite Delivery Contract (IDC) SPE2DU25D1008 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, with a ceiling value of $4,999,999, is for the provision of a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The solicitation for this IDC, referred to as the Pharmaceutical...
The Indefinite Delivery Contract (IDC) SPE2DR25D1102 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,999,999,999, covers the delivery of a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This includes specialty medications, brand-name and generic drugs,...
The Indefinite Delivery Contract (IDC) SPE2DR25D3301 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $999,999,999, is for the provision of a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This includes specialty medications, brand-name and generic drugs, vaccines,...
The indefinite delivery contract (IDC) SPE2DR25D1007 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide a comprehensive range of pharmaceutical products and medical supplies in support of military healthcare programs globally. The $9,999,999,999 single-award IDC has a 30-month base period with three 30-month option periods, totaling an estimated $30.3 billion in value. The contract...
The Indefinite Delivery Contract (IDC) SPE2DR25D3404 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,999,999,999, has an ultimate completion date of December 31, 2036 and serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally....
The Indefinite Delivery Contract (IDC) SPE2DR25D2105 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $999,999,999, covers the provision of a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This includes specialty medications, brand-name and generic drugs, vaccines,...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,999,999.00, will provide worldwide pharmaceutical support to various DoD customers, including the Defense Health Agency, Department of Defense, U.S. Coast Guard, and U.S. Naval Fleet, through the Pharmaceutical Prime Vendor Global Program...
The Indefinite Delivery Contract (IDC) SPE2DR25D3012 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $999,999,999 contract, which runs through December 2026, establishes AmerisourceBergen as a Pharmaceutical Prime Vendor to provide a comprehensive range of pharmaceutical products and medical supplies in support of military healthcare programs globally....
The Indefinite Delivery Contract (IDC) SPE2DU25D5117 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $999,999,999 and runs through December 2036, serving as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This includes...

The Indefinite Delivery Contract (IDC) SPE2DU25D1219 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,999,999.00, is for the provision of a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

The contract aims to establish Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contracts to provide worldwide pharmaceutical support to various DoD customers, including the Defense Health Agency (DHA), Department of Defense (DoD), United States Coast Guard, Designated Providers, Other Government Agencies, and the US Naval Fleet. The contract covers an extensive array of medical commodities, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. The contract has a 30-month base period and three 30-month option periods, with an estimated total value of $30.3 billion. The contract is an unrestricted, fully competitive acquisition, with multiple primary and backup suppliers to be awarded on a regional basis.

Generated 6/6/25, 10:10 AM